Titre :

Fermented infant formula (with bifidobacterium breve c50 and streptococcus thermophilus o65) with prebiotic oligosaccharides is safe and modulates the gut microbiota towards a microbiota closer to that of breastfed infants

Auteur(s) :

Beghin, Laurent [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Tims, Sebastian [Auteur]
Danone Nutricia Research [Utrecht]
Roelofs, Mieke [Auteur]
Danone Nutricia Research [Utrecht]
Rouge, Carole [Auteur]
Oozeer, Raish [Auteur]
Danone Nutricia Research [Utrecht]
Rakza, Thameur [Auteur]
Hôpital Jeanne de Flandre [Lille]
Chirico, Gaetano [Auteur]
Civic Hospital of Brescia
Roeselers, Guus [Auteur]
Danone Nutricia Research [Utrecht]
Knol, Jan [Auteur]
Danone Nutricia Research [Utrecht]
Wageningen University and Research [Wageningen] [WUR]
Roze, Jean-Christophe [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Turck, Dominique [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Hôpital Jeanne de Flandre [Lille]

Titre de la revue :

Clinical nutrition (Edinburgh, Scotland)

Nom court de la revue :

Clin Nutr

Date de publication :

2020-07-23

ISSN :

1532-1983

Mot(s)-clé(s) :

Early-life microbiota
Secretory IgA
Healthy term infants
Prebiotics
Fermented formula
Postbiotics

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

OBJECTIVE: Microbiome-modulators can help positively steer early-life microbiota development but their effects on microbiome functionality and associated safety and tolerance need to be demonstrated. We investigated the ...
Lire la suite >OBJECTIVE: Microbiome-modulators can help positively steer early-life microbiota development but their effects on microbiome functionality and associated safety and tolerance need to be demonstrated. We investigated the microbiome impact of a new combination of bioactive compounds, produced by the food-grade microorganisms Bifidobacterium breve C50 and Streptococcus thermophilus ST065 during a fermentation process, and prebiotics in an infant formula. Tolerance and safety were also assessed. METHODS: An exploratory prospective, randomized, double-blind, controlled, multi-centre study was designed to investigate the effect of bioactive compounds and prebiotics (short-chain galacto-oligosaccharides (scGOS)/long-chain fructo-oligosaccharides (lcFOS) 9:1). Experimental formulas containing these bioactive compounds and prebiotics (FERM/scGOS/lcFOS), prebiotics (scGOS/lcFOS), or bioactive compounds (FERM), were compared to a standard cow's milk-based control formula (Control). Exclusively breastfed infants were included as a reference arm since exclusive breastfeeding is considered as the optimal feeding for infants. The study lasted six months and included visits to health care professionals at baseline, two, four and six months of age. Stool SIgA concentration was the primary study outcome parameter. RESULTS: There were 280 infants randomized over the experimental arms and 70 infants entered the breastfed-reference arm. Demographics were balanced, growth and tolerance parameters were according to expectation and adverse events were limited. At four months of age the median SIgA concentration in the FERM/scGOS/lcFOS group was significantly higher compared to the Control group (p = 0.03) and was more similar to the concentrations found in the breastfed-reference group. Bifidobacterium increased over time in all groups. The FERM/scGOS/lcFOS combination resulted in a microbiota composition and metabolic activity closer to the breastfed infants' microbiome. CONCLUSIONS: The FERM/scGOS/lcFOS combination showed a significant positive effect on SIgA levels. All formulas tested were associated with normal growth and were well-tolerated. Additionally, at four months of age the FERM/scGOS/lcFOS formula brought the microbiome composition and metabolic activity closer towards that of breastfed infants. Registration number NTR2726 (Netherlands Trial Register; www.trialregister.nl/).Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2021-07-06T12:50:11Z
2024-02-06T09:56:21Z